15d-prostaglandin J2 Protects Brain from Ischemia-reperfusion Injury

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2005 Dec 31

PMID 16385084

Citations 62

Authors

Teng-Nan Lin

Wai-Mui Cheung

Jui-Sheng Wu

Jean-Ju Chen

Heng Lin

Jin-Jer Chen

Jun-Yang Liou

Song-Kun Shyue

Kenneth K Wu

Affiliations

Soon will be listed here.

Abstract

Objective: Brain expresses abundant lipocalin-type prostaglandin (PG) D2 (PGD2) synthase but the role of PGD2 and its metabolite, 15-deoxy-Delta(12,14) PGJ2 (15d-PGJ2) in brain protection is unclear. The aim of this study is to assess the effect of 15d-PGJ2 on neuroprotection.

Methods And Results: Adenoviral transfer of cyclooxygenase-1 (Adv-COX-1) was used to amplify the production of 15d-PGJ2 in ischemic cortex in a rat focal infarction model. Cortical 15d-PGJ2 in Adv-COX-1-treated rats was increased by 3-fold over control, which was correlated with reduced infarct volume and activated caspase 3, and increased peroxisome proliferator activated receptor-gamma (PPARgamma) and heme oxygenase-1 (HO-1). Intraventricular infusion of 15d-PGJ2 resulted in reduction of infarct volume, which was abrogated by a PPARgamma inhibitor. Rosiglitazone infusion had a similar effect. 15d-PGJ2 and rosiglitazone at low concentrations suppressed H2O2-induced rat or human neuronal apoptosis and necrosis and induced PPARgamma and HO-1 expression. The anti-apoptotic effect was abrogated by PPARgamma inhibition.

Conclusions: 15d-PGJ2 suppressed ischemic brain infarction and neuronal apoptosis and necrosis in a PPARgamma dependent manner. 15d-PGJ2 may play a role in controlling acute brain damage induced by ischemia-reperfusion.

Citing Articles

Conceptual foundations of acetylcarnitine supplementation in neuropsychiatric long COVID syndrome: a narrative review.

Helbing D, Dommaschk E, Danyeli L, Liepinsh E, Refisch A, Sen Z Eur Arch Psychiatry Clin Neurosci. 2024; 274(8):1829-1845.

PMID: 38172332 PMC: 11579146. DOI: 10.1007/s00406-023-01734-3.

Activating Transcription Factor 3 Diminishes Ischemic Cerebral Infarct and Behavioral Deficit by Downregulating Carboxyl-Terminal Modulator Protein.

Kao M, Huang C, Cheung W, Yan Y, Chen J, Ho Y Int J Mol Sci. 2023; 24(3).

PMID: 36768628 PMC: 9917101. DOI: 10.3390/ijms24032306.

Induction of Heme Oxygenase-1 by 15d-Prostaglandin J Mediated via a ROS-Dependent Sp1 and AP-1 Cascade Suppresses Lipopolysaccharide-Triggered Interleukin-6 Expression in Mouse Brain Microvascular Endothelial Cells.

Yang C, Hsiao L, Shih Y, Chang C, Yang C Antioxidants (Basel). 2022; 11(4).

PMID: 35453404 PMC: 9024691. DOI: 10.3390/antiox11040719.

Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ Attenuates HO-Induced IL-6 Expression in Rat Brain Astrocytes.

Wang C, Yang C, Hsiao L, Yang C Neurotox Res. 2022; 40(1):154-172.

PMID: 34997457 PMC: 8784370. DOI: 10.1007/s12640-020-00318-6.

Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration.

Durai P, Beeraka N, Ramachandrappa H, Krishnan P, Gudur P, Raghavendra N Curr Neuropharmacol. 2021; 20(5):893-915.

PMID: 34751120 PMC: 9881103. DOI: 10.2174/1570159X19666211109141330.